Sichuan Kaijing Pharmaceutical

Sichuan Kaijing Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the development of innovative small molecule drugs. The company's research focus is primarily on oncology and metabolic diseases, aiming to address significant unmet medical needs through precision medicine. Its lead candidate, KJ-01, is a highly selective inhibitor of Ubiquitin Specific Peptidase 1 (USP1) currently in Phase 1/2 clinical trials for advanced solid tumors, particularly those with DNA damage response deficiencies. Supported by prominent investors like HighLight Capital and SDIC Unity Capital, the company continues to expand its pipeline of targeted therapies. Kaijing Pharmaceutical leverages its internal R&D platform to discover potent and selective molecules for complex biological targets.